Literature DB >> 2935075

Concentration-dependent effects of foscarnet on the cell cycle.

K Stenberg, S Skog, B Tribukait.   

Abstract

The mechanism of toxicity of foscarnet was studied by monitoring its effects on the cell cycle of exponentially growing, semisynchronous human embryo cells in culture. The effects of foscarnet on the cell cycle were dependent on the concentration of drug used. At 1 mM, cell division was reduced by 50%, whereas the cell flow was mainly reduced in the G2 phase of the cell cycle, leading to an increase in the proportion of G2+M cells. The minor reduction of thymidine incorporation in S phase cells provided additional evidence that 1 mM foscarnet did not specifically inhibit DNA synthesis. Cell division was greatly reduced at 2.5 mM foscarnet, and the G2 phase was markedly affected, whereas S cell flow was less reduced. S cell flow was 10% per h and thymidine incorporation was 25% that of control cells, while a block in the G2+M phase was evident. On the other hand, at a concentration of 5 mM foscarnet, the cell flow was greatly reduced in the G1 and S phases, with less reduction of G2 cell flow and cells accumulated in the S phase. The effects of foscarnet on the cell cycle were more pronounced with increasing times up to 72 h, which could not be explained by the slow penetration of foscarnet which required only 4 to 8 h to achieve constant levels. At 2.5 and 5 mM foscarnet, there was the additional effect of the cell membranes becoming more leaky as a result of foscarnet toxicity which might contribute to the toxic effects of the drug at high concentrations. When foscarnet was removed from the medium, the effects on the cell cycle were rapidly reversed, in the time needed for foscarnet to diffuse out from the cells, which indicates the reversible nature of the toxic effects of foscarnet.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2935075      PMCID: PMC180332          DOI: 10.1128/AAC.28.6.802

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Trisodium phosphonoformate, a new antiviral compound.

Authors:  E Helgstrand; B Eriksson; N G Johansson; B Lannerö; A Larsson; A Misiorny; J O Norén; B Sjöberg; K Stenberg; G Stening; S Stridh; B Oberg
Journal:  Science       Date:  1978-09-01       Impact factor: 47.728

2.  Inhibition of herpesvirus replication and herpesvirus-induced deoxyribonucleic acid polymerase by phosphonoformate.

Authors:  J M Reno; L F Lee; J A Boezi
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

3.  Cellular toxicity of pyrophosphate analogues.

Authors:  K Stenberg
Journal:  Biochem Pharmacol       Date:  1981-05-01       Impact factor: 5.858

4.  Analysis of cell flow and cell loss following X-irradiation using sequential investigation of the total number of cells in the various parts of the cell cycle.

Authors:  S Skog; B Tribukait
Journal:  Cell Tissue Kinet       Date:  1985-07

5.  Cell cycle analysis by flow cytometry.

Authors:  J W Gray; P Coffino
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

6.  Inhibition of eucaryotic DNA polymerases by phosphonoacetate and phosphonoformate.

Authors:  C L Sabourin; J M Reno; J A Boezi
Journal:  Arch Biochem Biophys       Date:  1978-04-15       Impact factor: 4.013

7.  Reversible effects on cellular metabolism and proliferation by trisodium phosphonoformate.

Authors:  K Stenberg; A Larsson
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

8.  Aphidicolin inhibits cell growth by accumulation of G2 cells.

Authors:  M Fukuda; M Ohashi
Journal:  Cell Biol Int Rep       Date:  1983-08

9.  Effects of foscarnet on the cell kinetics of Madin-Darby canine kidney cells.

Authors:  K Stenberg; S Skog; B Tribukait
Journal:  Biochim Biophys Acta       Date:  1983-02-16

Review 10.  Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Authors:  B Oberg
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

View more
  5 in total

Review 1.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

2.  Quantitative analysis of antiviral drug toxicity in proliferating cells.

Authors:  K Stenberg; J Wangenheim; B Tribukait
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

3.  Dynamics of Human Cytomegalovirus Infection in CD34+ Hematopoietic Cells and Derived Langerhans-Type Dendritic Cells.

Authors:  Roxanne Coronel; Sachiko Takayama; Timothy Juwono; Laura Hertel
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

4.  PUL21a-Cyclin A2 interaction is required to protect human cytomegalovirus-infected cells from the deleterious consequences of mitotic entry.

Authors:  Martin Eifler; Ralf Uecker; Henry Weisbach; Boris Bogdanow; Ellen Richter; Lydia König; Barbara Vetter; Tihana Lenac-Rovis; Stipan Jonjic; Heidemarie Neitzel; Christian Hagemeier; Lüder Wiebusch
Journal:  PLoS Pathog       Date:  2014-11-13       Impact factor: 6.823

Review 5.  Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.

Authors:  Lauren A Sadowski; Rista Upadhyay; Zachary W Greeley; Barry J Margulies
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.